PL446346A1 - Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta - Google Patents

Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta

Info

Publication number
PL446346A1
PL446346A1 PL446346A PL44634623A PL446346A1 PL 446346 A1 PL446346 A1 PL 446346A1 PL 446346 A PL446346 A PL 446346A PL 44634623 A PL44634623 A PL 44634623A PL 446346 A1 PL446346 A1 PL 446346A1
Authority
PL
Poland
Prior art keywords
disease
patient
risk
determining
level
Prior art date
Application number
PL446346A
Other languages
English (en)
Other versions
PL248077B1 (pl
Inventor
Waldemar Wierzba
Artur Zaczyński
Robert Gil
Agnieszka Pawlak
Original Assignee
Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych I Administracji
Biolab Genetic Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych I Administracji, Biolab Genetic Spółka Z Ograniczoną Odpowiedzialnością filed Critical Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych I Administracji
Priority to PL446346A priority Critical patent/PL248077B1/pl
Publication of PL446346A1 publication Critical patent/PL446346A1/pl
Priority to PCT/PL2024/050073 priority patent/WO2025080149A1/en
Publication of PL248077B1 publication Critical patent/PL248077B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ujawniono sposób badania obecności dwóch polimorfizmów genetycznych, których występowanie istotnie modyfikuje przebieg choroby COVID-19, sposób ten stanowi nowe narzędzie w ochronie populacji przed chorobą COVID-19.
PL446346A 2023-10-10 2023-10-10 Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta PL248077B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL446346A PL248077B1 (pl) 2023-10-10 2023-10-10 Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta
PCT/PL2024/050073 WO2025080149A1 (en) 2023-10-10 2024-10-10 Method for determining the level of risk of severe covid-19 disease in a patient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL446346A PL248077B1 (pl) 2023-10-10 2023-10-10 Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta

Publications (2)

Publication Number Publication Date
PL446346A1 true PL446346A1 (pl) 2024-07-29
PL248077B1 PL248077B1 (pl) 2025-10-13

Family

ID=91971279

Family Applications (1)

Application Number Title Priority Date Filing Date
PL446346A PL248077B1 (pl) 2023-10-10 2023-10-10 Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta

Country Status (2)

Country Link
PL (1) PL248077B1 (pl)
WO (1) WO2025080149A1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022120130A1 (en) * 2020-12-03 2022-06-09 Regeneron Pharmaceuticals, Inc. Methods of identifying subjects having an increased risk of developing a coronavirus infection and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4158067A4 (en) * 2020-05-27 2024-09-25 Genetic Technologies Limited Methods of assessing risk of developing a severe response to coronavirus infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022120130A1 (en) * 2020-12-03 2022-06-09 Regeneron Pharmaceuticals, Inc. Methods of identifying subjects having an increased risk of developing a coronavirus infection and treatment thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERREIRA, L.C. I IN.: "Genetics and Evolution 106 (2022) 105379", "GENOME-WIDE ASSOCIATION STUDIES OF COVID-19: CONNECTING THE DOTS" *
PAIRO-CASTINEIRA, E. I IN.: "Nature (2021): 591(7848): 92-98", "GENETIC MECHANISMS OF CRITICAL ILLNESS IN COVID-19" *

Also Published As

Publication number Publication date
PL248077B1 (pl) 2025-10-13
WO2025080149A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
MX2021010701A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad.
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
MA43335A (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
ECSP099239A (es) Determinadas amidas sustituidas, método de elaboración y método de uso de las mismas
CL2022002095A1 (es) Composiciones y métodos para la edición génica de calicreína (klkb1)
GEAP202316332A (en) Cdk2 inhibitors and methods of using the same
BR112021012654A2 (pt) Métodos de tratamento de infecções por tempestade de citocina, incluindo covid-19, através da inibição da interação ccr5/ccl5 (rantes) e composições para a prática da mesma
CL2025001827A1 (es) Inhibidores de malt1
CO2018001599A2 (es) Un inhibidor de anticuerpo monoclonal de factor xiia
BR112017024853A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
MX2022007626A (es) Combinaciones.
MX2022007628A (es) Combinaciones.
MX2023013412A (es) Métodos y composiciones para monitorear el tratamiento de mieloma múltiple recidivante y/o refractario.
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2025006740A (es) Composiciones farmacéuticas que contienen una de piperidinil-metil-purina amina y su uso en el tratamiento de enfermedades y afecciones
PL446346A1 (pl) Sposób określania poziomu ryzyka ciężkiego przebiegu choroby COVID-19 u pacjenta
MA39496A (fr) Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x
EP4233807C0 (de) Anpassbare gamasche, insbesondere für pferde
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
JOP20210216A1 (ar) علاج السرطان
SA522432781B1 (ar) مركب مضاد pd-l1
CL2025000223A1 (es) Formulaciones de anticuerpos contra tl1a